Erratum

Correction to: NEXThaler, an innovative dry powder inhaler delivering an extrafine fixed combination of beclometasone and formoterol to treat large and small airways in asthma.

Corradi M, Chrystyn H, Cosio BG et al. NEXThaler, an innovative dry powder inhaler delivering an extrafine fixed combination of beclometasone and formoterol to treat large and small airways in asthma. Expert Opin. Drug Deliv. 2014:11 (9):1497-506

Following publication of this article, errors were identified in the Declaration of interest section. The correct disclosure is given below.

Declaration of interest:
Massimo Corradi has received honoraria for presentations and consultant agreements from Chiesi Farmaceutici SpA. Borja has received sponsorship for research studies, consultant agreements and honoraria for presentations from several pharmaceutical companies that market inhaled products including Almirall, AstraZeneca, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Novartis and Menarini. Renault Louis has unrestricted research grants from GlaxoSmithKline, Novartis, AstraZeneca and Chiesi. Dr Louis has received speaker or board honoraria from GlaxoSmithKline, AstraZeneca, and Mundipharma. Michal Pirozynski has received honoraria for lectures from the following companies: Abbott, AstraZeneca, Chiesi, GlaxoSmithKline, Hasco, Meda, Olympus, Servier and Teva. Stelios Loukides has received honoraria for presentations and is on the advisory board for several companies including AstraZeneca (Greece, Poland, Bulgaria), Boehringer Ingelheim (Greece), Chiesi Hellas, GlaxoSmithKline (Greece, Denmark), Elpen, MSD, Novartis Hellas, UCB and Takeda. Monica Spinola is an employee of Chiesi Farmaceutici SpA. Henry Chrystyn has received sponsorship to carry out research studies together with some consultant agreements and honoraria for presentations from several companies that market inhaled products. These include Almirall, AstraZeneca, Boehringer Ingelheim, Chiesi, Cipla, GlaxoSmithKline, Innovata Biomed, Meda, Mundipharma, Orion, Teva, Truddell Medical International, UCB and Zentiva. Research sponsorship has also been received from grant awarding bodies, EPSRC and MRC. Dr Omar Usmani is a recipient of a UK NIHR (National Institute for Health Research) Career Development Fellowship and supported by the NIHR Respiratory Disease Biomedical Research Unit at the Royal Brompton and Harefield NHS Foundation Trust and Imperial College London. He has received sponsorship for symposium talks and financial assistance to attend advisory boards for the following organizations: Aerocrine, Novartis, Almirall, Pieris-AG, AstraZeneca, Philips Respironics, Boehringer Ingelheim, Pfizer, Chiesi, Prosonix, Edmond Pharma, Sandoz, GlaxoSmithKline, Takeda, MicroDose Therapeutx, UCB, Mundipharma, Zentiva and NAPP.